Q&A: Mesenchymal stem cells — where do they come from and is it important? by Iain R. Murray & Bruno Péault
Murray and Péault BMC Biology  (2015) 13:99 
DOI 10.1186/s12915-015-0212-7QUESTION AND ANSWER Open AccessQ&A: Mesenchymal stem cells — where do
they come from and is it important?
Iain R. Murray1 and Bruno Péault1,2*Abstract
Mesenchymal stem — or stromal — cells (MSCs) have
been administered in hundreds of clinical trials for
multiple indications, making them some of the most
commonly used selected regenerative cells.
Paradoxically, MSCs have also long remained the least
characterized stem cells regarding native identity and
natural function, being isolated retrospectively in
long-term culture. Recent years have seen progress in
our understanding of the natural history of these cells,
and candidate native MSCs have been identified
within fetal and adult organs. Beyond basic
knowledge, deciphering the biology of innate MSCs
may have important positive consequences for the
therapeutic use of these cells.support, albeit limited, of hematopoiesis.What are mesenchymal stem cells, and how are
they conventionally isolated?
Mesenchymal stem cells (MSCs) are multipotent stromal
cells that can differentiate into a variety of lineages, in-
cluding osteocytes, adipocytes and chondrocytes. This
differentiation capacity, in addition to their release of
trophic factors and immunomodulatory properties, holds
great promise for cell therapies and tissue engineering.
MSCs are not a new phenomenon. In the late nineteenth
century the German biologist Cohnheim hypothesized
that fibroblastic cells derived from bone marrow were
involved in wound healing throughout the body [1]. In
the 1970s Alexander Friedenstein, who is generally cred-
ited with the discovery of MSCs, described a population
of plastic-adherent cells that emerged from long-term
cultures of bone marrow and other blood-forming or-
gans, and that he showed to have colony forming
capacity and osteogenic differentiation characteristics* Correspondence: bpeault@mednet.ucla.edu
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In light of their capacity to differentiate into bone, fat,
cartilage and muscle in culture and an emerging link to
the embryonic development of various mesenchymal tis-
sues, the term “mesenchymal stem cell” was coined in
1991 by Arnold Caplan to describe these cells [5]. Cells
with similar characteristics have since been found to
emerge from cultures of virtually all adult and fetal organs
tested [6]. Observation of these cells in culture led to a
definition of MSCs by the International Society of Cell
Therapy (ISCT) that included a propensity to adhere to la-
boratory culture plastic and the capacity to differentiate
into at least bone, cartilage and fat [7]. MSCs were subse-
quently found to have a characteristic, although not spe-
cific, set of surface markers, with additional functions
including the secretion of immunomodulatory factors and
This body of work suggested that MSCs natively re-
sided in all the tissues from which they were isolated;
however, their exact location (whether in the stroma or,
for instance, in blood vessels) was still not known. An
improved understanding of the native identity and biol-
ogy of these cells has recently been sought.Is it important to understand the native origin of
MSCs?
Yes, a complete understanding of the native origin of
MSCs will allow their therapeutic potential to be fully
exploited. The documented multipotency, immunomod-
ulatory and trophic effects of MSCs sparked great excite-
ment and enthusiasm to explore the use of MSCs as
progenitors in tissue engineering to replace damaged tis-
sues of mesodermal and possibly other germ line origins,
to promote regeneration, and to treat immune-mediated
disease [8]. As such, the number of clinical trials using
MSCs has been rising almost exponentially since 2004.
However, with the “gold rush” to use MSCs in the clin-
ical setting, the question of what MSCs naturally do in
bone marrow and other tissues, and what intrinsic roles
these populations may play in vivo, beyond how theirarticle is distributed under the terms of the Creative Commons Attribution 4.0
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culture-related artificial cues or settings, were not
understood. Cells were being used for therapeutic pur-
poses without a true understanding of their native ori-
gin or function. An improved understanding of their
location and function within tissues would not only sat-
isfy scientific curiosity but also facilitate potential thera-
peutic targeting of these cells.
Are MSCs artifacts of culture, or do identical cells
natively reside in tissues, and if so, where?
The answer to that remained obscure for many years. As
described above, MSCs have historically been isolated in
culture, being selected from total cell suspensions based
on their ability to adhere and proliferate for several
weeks of primary cultivation. At difference with, for in-
stance, hematopoietic stem cells, which were initially
identified within mixed cell populations then increas-
ingly enriched with markers and eventually purified to
homogeneity from the bone marrow, MSCs remained
for decades retrospectively isolated cells of unknown na-
tive identity, tissue distribution, frequency, or natural
function in vivo [6]. Typically, the MSC description pro-
vided by ISCT in 2006 — that is, 40 years after Frieden-
stein’s original observations — still relied exclusively on
markers defined in culture, giving no clue as to the in-
nate character of these cells in vivo. With these cells
having been only identified in a process requiring long-
term culture and a definition based entirely on in vitro
characteristics, it has been proposed by some that MSCs
merely represent an artifact of culture. This is supported
by a body of literature confirming that cell phenotypes
are altered by exposure to culture products and adher-
ence to stiff culture matrices. However, a number of
large-scale studies of multiple human tissues have identi-
fied vascular pericytes (which ensheathe capillaries and
microvessels in all tissues) by immunohistochemistry,
and then purified those to homogeneity by flow cytometry
[9]. Cultured pericytes, notwithstanding tissue of origin,
turned out to be indistinguishable from conventional
MSCs in terms of adherence, morphology, phenotype,
proliferation rate, and developmental potential. Import-
antly, native expression of the MSC markers CD73, CD90,
and CD105 by human pericytes is now well established,
further supporting the hypothesis that both cell types are
affiliated [9]. Altogether, these results designated micro-
vascular pericytes as at least one class of tissue-resident
MSCs, even though it was not known whether these peri-
vascular cells in situ could also be functionally qualified as
MSCs, or were only the precursors thereof.
Are pericytes the only natural source of MSCs?
No. Pericytes are not the only perivascular cells endowed
with potential to give rise to MSCs, which are thereforenot necessarily associated with capillaries and microves-
sels. A population of progenitors located in the outmost
layer of larger arteries and veins, the tunica adventitia,
has also been identified as a source of bona fide MSCs
[10]. Adventitial progenitors are phenotypically and ana-
tomically distinct from pericytes. However, like pericytes,
adventitial cells natively express MSC markers. In this
regard, pericytes and adventitial cells have been collect-
ively termed perivascular stem cells or PSCs (Fig. 1).
Although experimental evidence points to a perivascu-
lar origin of culture-selected MSCs, the possibility that
non-vascular cells in some tissues can yield MSCs in
culture cannot be excluded. In support of this it has re-
cently been observed that a subset of osteogenic progen-
itors that exhibit MSC potential reside within cranial
sutures but do not appear to be associated with blood
vessels [11]. However, it remains to be demonstrated
that such progenitor cells are not affiliated with perivas-
cular cells that emerged earlier in development, but
eventually migrated away from the vascular niche.
How do native MSCs support tissue regeneration?
Although the multipotent, immunomodulatory and
trophic effects of MSCs demonstrated in culture hold
great promise for cell therapy [12], whether these MSCs
also play a natural role in tissue regeneration in vivo is
not yet fully established. The discovery that pericytes
represent innate MSCs has greatly facilitated our under-
standing of the native roles of MSCs, as these cells can
now be studied in vivo and their fates explored through
lineage tracing using established pericyte markers [13].
Recent publications have already documented the direct
involvement of perivascular progenitor cells in the devel-
opment and/or regeneration of white adipocytes [14],
skeletal muscle [15], follicular dendritic cells [16] and
dental pulp [13]. Altogether, these observations suggest
the presence in the adult of regenerative cells associated
with all blood vessels, hence broadly disseminated
throughout the organism. Intriguingly, pericyte contribu-
tion to musculoskeletal tissue development and regener-
ation is not absolute and varies with anatomical location.
For example, the contribution of pericytes to myofibers
varies among different muscles, ranging from <1 % (tibi-
alis anterior muscle) to 7 % (diaphragm) of the fibers and
is enhanced (although only modestly) by acute or chronic
muscle regeneration [15].
The number of molecules known to mediate the para-
crine action of MSCs continues to increase [17]. MSC
paracrine effects demonstrated in vitro can be divided
into trophic, immunomodulatory and chemoattractant
[18]. The trophic effects of MSCs include the inhibition
of apoptosis, support of regeneration and stimulation,
maintenance, proliferation and differentiation of tissue-




Fig. 1. MSCs reside in perivascular locations in vivo as pericytes and adventitial cells. Fluorescent micrograph (a) and schematic (b) illustrating the
intimate relationship between microvascular pericytes (CD146+CD34−) and endothelial cells (CD146+/−CD34+). Note that the blue/purple color
indicates DAPI staining within nuclei of both cell types. Endothelial cells appear yellow/green because they express both CD146 (here in red) and
CD34 (here in green). Adventitial cells (CD34+CD146−) located in the outmost layer of larger arteries and veins, the tunica adventitia, have also
been identified as a source of bona fide MSCs (c, d). Smooth muscle cells around some larger vessels, which are perivascular but not sensu stricto
pericytes, also express CD146, illustrating that marker expression must be assessed in combination with microanatomy
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stem cells in a number of settings, including ischemic
brain injury [20]. Hypoxia takes place in the initial stages
of tissue injury and secretion of anti-apoptotic factors by
MSCs minimizes the extent of cell death in the tissues
surrounding the injured areas. Re-establishment of blood
supply is fundamental for recovery of damaged tissues
and the pro-angiogenic effect of MSCs has been demon-
strated in murine models of hind-limb ischemia [21].
Furthermore, the transition back to a pericyte phenotype
serves to stabilize the forming vasculature both in vitro
and in vivo [22]. The immunomodulatory properties of
bone marrow-derived MSCs, including their immuno-
suppressive effects during allogeneic stem cell trans-
plantation, have been well documented [23–27]. The
immunoactivity of the cells is mediated by direct cell–
cell contact and through secreted bioactive molecules
involving dendritic cells and B and T cells, including T
regulatory cells and T helper cells as well as killer cells.
MSCs also secrete a variety of chemoattractant mole-
cules. Target cells for these include monocytes, eosino-
phils, neutrophils, basophils, memory and naïve T cells,
B cells, natural killer cells, dendritic cells and endothelial
cell progenitors. It is likely that the pattern of chemokine
expression by MSCs is modified by exposure to other
cell types, particularly immune cells. As can be seen
from above, native MSCs use a variety of processes and
molecules to support tissue regeneration.Do native MSCs exert exclusively beneficial
effects?
No. There is increasing evidence to support a central
role for pericytes in tissue fibrosis [28, 29]. Fibrosis is
the pathological persistent accumulation of collagenous
extracellular matrix that can impair tissue function in a
large variety of vital organs and tissues. Despite the di-
verse range of tissues susceptible to fibrosis, all fibrotic
reactions share common cellular and molecular mecha-
nisms [30]. Often starting as a beneficial physiological
repair response to organ injury with hemostatic, inflam-
matory and remodeling phases, fibrosis is characterized
by the persistent activity of matrix remodeling myofibro-
blasts. Several recent studies using cutting edge murine
genetic cell labeling techniques have identified pericytes
as major myofibroblast progenitors in multiple organs
[28, 29]. Similarly, studies have emerged implicating
pathological differentiation of MSCs in the development
of heterotopic ossification [31]. As such it is not likely
that the detrimental effects are a ‘normal’ function, ra-
ther a pathology that occurs when normal function be-
comes dysregulated.
Are MSCs true stem cells?
This is a source of much dispute within the MSC litera-
ture [32, 33]. Stem cells are strictly defined by their abil-
ity to reconstruct the tissue of origin in vivo while also
contributing to its maintenance and repair — thus
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renew. Stem cells differ from progenitor cells (or transi-
ent amplifying cells) that exhibit extended proliferative
capacity and differentiation in vitro but have little ability
to contribute to long-term tissue regeneration in vivo.
Hematopoietic stem cells (HSCs) are the best character-
ized adult stem cells, and therefore are often used as a
benchmark as to the level of evidence required to dem-
onstrate the defining criteria of stem cells. HSCs can
give rise to all blood cell components, including neutro-
phils, lymphocytes, natural killer cells, dendritic cells,
macrophages and monocytes. MSCs derived from mul-
tiple sources have similarly been shown to give rise to
osteoblasts, chondrocytes, adipocytes and reticular
stroma. Stem cells also possess the ability to undergo
numerous cell divisions while retaining their stem cell
identity; that is, they have the capacity for self-renewal.
For example, HSCs transplanted into irradiated mice
can reconstitute the entire hematopoietic system while
also giving rise to further HSCs that can be serially re-
transplanted [34]. Transplantation of bone marrow-
resident MSCs gives rise to ‘ossicles’ composed of bone,
cartilage and reticular stroma, as well as to a population
of serially re-transplantable MSCs [35, 36]. Despite this,
there is very little evidence for long-term skeletal regener-
ation of MSCs in vivo. Transplantation of MSCs through
intravenous infusion has resulted in little or no engraft-
ment of cells to bone or bone marrow. However, intra-
femoral injection of a subset of murine marrow stromal
cells has shown limited engraftment at the site of injection
4–6 weeks post-transplantation, suggesting that the quality
of the cells injected as well as the route of injection are
major determinants of engraftment [37, 38]. In other
words, MSCs obviously self-renew in culture, which guar-
antees the sustained presence of regenerative cells over
many passages and, accordingly, express factors known to
regulate the self-renewal of other, better characterized stem
cells [39]. By contrast, whether MSCs re-transplanted
in vivo behave like bona fide stem cells in terms of renewal
is dubious. Regarding MSC natural origin in situ, quiescent
perivascular cells presumably lose contact with blood ves-
sels to be reprogrammed into stem/regenerative cells.
Whether MSCs that arise this way also undergo self-
renewal or are fully consumed in the tissue repair response
is unknown. In fine, the self-renewing MSC might well be
confined to the culture flask.
Can native MSCs be purified without a
requirement for cell culture?
Traditional methods of MSC isolation have depended on
a period of cell culture for two reasons. Firstly, as the
exact location or phenotype of MSCs in tissues was not
known, it was not possible to target specifically these
cells for purification. Instead researchers had to wait forthese cells to emerge from cell culture where they would
overgrow other cell types. Recent insights into the peri-
vascular origin of MSCs combined with advances in
multicolor flow cytometry have overcome this, enabling
prospective purification of innate MSCs to homogeneity
on the basis of established pericyte and adventitial cell
markers [40]. All vascularized tissues are now possible
immediate sources of purified MSCs, which can now be
isolated using fluorescence activated cell sorting (FACS).
The second reason for historic dependence on culture
has been the need to expand cell populations to clinically
relevant numbers [12]. Low stem cell yield and donor site
morbidity limit the use of fresh autologous bone marrow,
periosteum and the majority of other MSC sources [6].
FACS purification of perivascular cells has highlighted the
varying abundance of MSCs within different organs. Rela-
tive to the lower yield, limited donor sites, and morbidity
associated with bone marrow or periosteal harvest, adi-
pose tissue is now a well-documented, easily accessible,
abundant and dispensable source of perivascular MSCs
[41]. Approximately 15 million perivascular MSCs can be
purified per 100 ml of lipoaspirate — a sufficient number
of cells to treat a broad range of musculoskeletal disorders
without culture expansion [42]. So the answer is yes,
MSCs can now be isolated without the need for cell cul-
ture but not in high enough numbers to treat all current
clinical applications, for example, graft versus host disease
where multiple, large repeated doses are often required.
Why bother to purify MSCs anyway?
Whole bone marrow cell suspensions and the stromal
vascular fraction (SVF) of adipose tissue have been used
directly in therapeutic applications with the aim of harnes-
sing the potential of the contained stem cells. This type of
stem cell therapy is heavily studied by many biotech com-
panies developing benchtop systems that produce SVF at
the bedside, which makes the cell mixture conveniently
available shortly after harvesting adipose tissue through
liposuction. However, both represent highly heteroge-
neous cell populations, which include non-MSC types,
such as inflammatory cells, hematopoietic cells, endothe-
lial cells, and non-viable cells among others. Available
studies using SVF show poor and unreliable tissue forma-
tion [43], or lower tissue regeneration efficacy relative to
cultured MSCs [44]. In fact, recent studies have suggested
that the presence of endothelial cells has inhibiting effects
on bone differentiation, among other lineages [45]. Des-
pite the process of enrichment through plastic adherence,
it is inevitable that even cultured preparations will be con-
taminated by non-MSC populations, and the contribution
of each contained population to the repair process cannot
be definitively established.
In addition, variability in cell composition presents
clear barriers to approval from regulatory bodies such as
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cell-based therapeutics, potentially including reduced
safety, purity, identity, potency and efficacy [46]. With
these regulatory hurdles in mind, the use of purified pre-
sumptive MSCs, that is, pericytes and adventitial cells,
has clear practical advantages [12].
Why might it be advantageous to avoid cell
culture?
The selection and preparation of MSCs through adher-
ence to culture plastic is time consuming, and introduces
additional risks such as immunogenicity and infection
through exposure to animal-derived culture products. In-
vestigators have documented the influence of MSC culture
on genetic instability [47], and tumorigenicity [48, 49], al-
though these results have been challenged [48]. Multipo-
tentiality, hence therapeutic potency, has been shown to
diminish with serial passaging, with human bone-marrow
derived MSCs progressively losing their potential for adi-
pogenic and chondrogenic differentiation as the number
of cell divisions increases [50]. Regardless of the protocol
for culture expansion, MSCs undergo replicative senes-
cence in culture, limiting their clinical applications [51]. In
addition, expression of adhesion molecules and chemo-
kines, and the ability to respond to chemokines, decline
with time in culture [51].
Finally, almost immediate availability of autologous
presumptive MSCs would allow immediate treatment of
emergency conditions without depending on weeks of
in vitro culture to collect equivalent therapeutic cells.
The future: activating stem cells in their native
environment?
Possibly, yes. The widespread presence of MSCs through-
out vascularized organs equates to a reservoir of poten-
tially therapeutic regenerative units throughout the body.
This raises the possibility of using therapeutic strategies to
‘recruit’ or accelerate the regenerative capacity of resident
MSCs following injury. The ‘activation’ of adult stem cells
is known to be regulated, in part, by their neighboring
cells [52–54]; manipulation of this communication
through the local infiltration of growth factors or mole-
cules integral to this interaction may represent such an
approach, the ultimate goal being the manipulation and
activation of the regenerative potential of both local stem
cells and those recruited from distant sites. As MSCs are
ubiquitous amongst vascular tissues, controlled activation
of their potential would provide an alternative to purifi-
cation and transplantation in cases where the native
structural environment remains sufficiently intact to ac-
commodate repair. In situ activation of MSCs could be
harnessed to accelerate healing and facilitate an early re-
turn to function after a variety of musculoskeletal injur-
ies. Other potential applications of activating residentMSCs could also include the treatment of osteoporosis
and muscular dystrophies where local application of
MSCs alone is not practical. In summary, the controlled
activation of MSCs in their native environment will be
an important future therapeutic approach.
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